Tag: Huntington s chorea

Unlike many antipsychotic medications that are dopamine receptor antagonists, Ingrezza (valbenazine) works via a completely different pathway to manage movement disorders. The crucial question, 'Is Ingrezza a dopamine blocker?' can be answered by examining its distinct mechanism of action as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor.

According to studies, symptoms of tardive dyskinesia can return within four weeks of discontinuing Ingrezza, while chorea symptoms associated with Huntington's disease can return within two weeks. Therefore, understanding **what happens if I stop taking Ingrezza** and the risks of doing so is crucial for anyone on this medication.